Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24226Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Daskalopoulou, S. S. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Wierzbicki, A. S. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:39:14Z | - |
| dc.date.available | 2015-11-24T19:39:14Z | - |
| dc.identifier.issn | 0300-7995 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24226 | - |
| dc.rights | Default Licence | - |
| dc.subject | Coronary Artery Disease/etiology/prevention & control | en |
| dc.subject | Fatty Acids, Monounsaturated/adverse effects/*pharmacology/therapeutic use | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse | en |
| dc.subject | effects/*pharmacology/therapeutic use | en |
| dc.subject | Hypercholesterolemia/complications/*drug therapy | en |
| dc.subject | Indoles/adverse effects/*pharmacology/therapeutic use | en |
| dc.subject | Lipids/*blood | en |
| dc.subject | Randomized Controlled Trials as Topic | en |
| dc.subject | Treatment Outcome | en |
| dc.title | A review of the lipid-related effects of fluvastatin | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1185/030079905X26261 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/15801994 | - |
| heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.1185/030079905X26261 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2005 | - |
| heal.abstract | BACKGROUND: Statin therapy has been shown to significantly decrease vascular events and overall mortality in primary and secondary prevention trials. This review considers the pharmacology, nonlipid-lowering effects and clinical trial evidence of fluvastatin based on a survey of PubMed entries. FINDINGS: Recent clinical data show that treatment with fluvastatin is associated with a variety of benefits in different high-risk populations along with a good safety profile. Fluvastatin exerts non-lipid lowering-associated pleiotropic effects in both clinical and experimental studies. Furthermore, an extended-release formulation of fluvastatin with a favourable pharmacokinetic profile is available. CONCLUSION: Treatment with fluvastatin offers a convenient, safe and evidence-based approach to managing dyslipidaemias and preventing vascular events. | en |
| heal.journalName | Current Medical Research and Opinion | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
